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Summary
Background In chronic central serous chorioretinopathy (CSCR), fluid accumulates in the subretinal space. CSCR is a 
common visually disabling condition that develops in individuals up to 60 years of age, and there is no definitive 
treatment. Previous research suggests the mineralocorticoid receptor antagonist, eplerenone, is effective for treating 
CSCR; however, this drug is not licensed for the treatment of patients with CSCR. We aimed to evaluate whether 
eplerenone was superior to placebo in terms of improving visual acuity in patients with chronic CSCR.
Methods This randomised, double-blind, parallel-group, multicentre placebo-controlled trial was done at 22 hospitals 
in the UK. Participants were eligible if they were aged 18–60 years and had had treatment-naive CSCR for 4 months or 
more. Patients were randomly assigned (1:1) to either the eplerenone or the placebo group by a trial statistician through 
a password-protected system online. Allocation was stratified by best-corrected visual acuity (BCVA) and hospital. 
Patients were given either oral eplerenone (25 mg/day for 1 week, increasing to 50 mg/day for up to 12 months) plus 
usual care or placebo plus usual care for up to 12 months. All participants, care teams, outcome assessors, pharmacists, 
and members of the trial management group were masked to the treatment allocation. The primary outcome was 
BCVA, measured as letters read, at 12 months. All outcomes apart from safety were analysed on a modified intention-
to-treat basis (participants who withdrew consent without contributing a post-randomisation BCVA measurement 
were excluded from the primary analysis population and from most secondary analysis populations). The trial is 
registered with ISRCTN, ISRCTN92746680, and is completed.
Findings Between Jan 11, 2017, and Feb 22, 2018, we enrolled and randomly assigned 114 patients to receive either 
eplerenone (n=57) or placebo (n=57). Three participants in the placebo group withdrew consent without contributing 
a post-randomisation BCVA measurement and were excluded from the primary outcome analysis population. All 
patients from the eplerenone group and 54 patients from the placebo group were included in the primary outcome. 
Modelled mean BCVA at 12 months was 79·5 letters (SD 4·5) in the placebo group and 80·4 letters (4·6) in the 
eplerenone group, with an adjusted estimated mean difference of 1·73 letters (95% CI –1·12 to 4·57; p=0·24) at 
12 months. Hyperkalaemia occurred in eight (14%) patients in each group. No serious adverse events were reported in 
the eplerenone group and three unrelated serious adverse events were reported in the placebo group (myocardial 
infarction [anticipated], diverticulitis [unanticipated], and metabolic surgery [unanticipated]).
Interpretation Eplerenone was not superior to placebo for improving BCVA in people with chronic CSCR after 12 months 
of treatment. Ophthalmologists who currently prescribe eplerenone for CSCR should discontinue this practice.
Funding Efficacy and Mechanism Evaluation Programme, and National Institute for Health Research and Social Care.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Central serous chorioretinopathy (CSCR) is the fourth 
most common retinal disease after neovascular age-
related macular degeneration, diabetic macular oedema, 
and retinal venous occlusion.1 Ten per 100 000 men and 
two per 100 000 women in the population develop CSCR 
each year.2 The condition is characterised by subretinal 
fluid (SRF) accumulation, which results in central visual 
disturbance when located subfoveally. CSCR is frequently 
bilateral and most patients exhibit signs of CSCR in both 
eyes.3 In most patients, the first episode of CSCR resolves 
spontaneously within 3 months of onset. When SRF 
persists beyond 3 months, the condition is considered to 
be chronic and can lead to permanent vision loss in up to 
a third of patients.4 CSCR can occur in families and some 
genetic associations have been reported.5–8
Little progress has been made in understanding CSCR 
since it was first described in 1866.9 Various treatments 
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have been used to treat CSCR despite scarce high-quality 
evidence to support their effectiveness. Verteporfin 
photodynamic laser therapy (vPDT) is used to treat some 
patients with CSCR. Randomised controlled trials of 
half-dose vPDT have shown some encouraging results in 
the short term.10,11 However, most hospitals do not have 
access to this treatment, as it requires a specialised laser. 
In addition, verteporfin is not licensed for the treatment 
of CSCR and it is expensive. Other types of laser 
treatments have been tried but there is scarce evidence to 
support their effectiveness and no randomised placebo-
controlled trials have been done to test their efficacy.10,12,13
Advances in retinal imaging have shown that eyes with 
CSCR have a thickened choroid and dilated choroidal 
vessels. In addition, previous studies14,15 suggest that CSCR 
is associated with choroidal hyperpermeability. In a rat 
model of CSCR, choroidal vasodilation was induced 
by aldosterone (a mineralocorticoid receptor activator) 
acting via an endothelial vasodilatory potassium channel, 
known as KCa2.3. Inhibition of this pathway prevented 
aldosterone-induced choroidal thickening, suggesting 
that mineralocorticoid receptor activation might con-
tribute to the pathogenesis of CSCR.16 Subsequently, 
case series of patients with chronic CSCR who were given 
oral mineralocorticoid receptor antagonists, such as 
eplerenone (a specific antagonist licensed for use in 
patients with heart failure) and spironolactone (a non-
specific anta gonist), have reported resolution of SRF, a 
reduction in choroidal thickening, and improvements 
in visual acuity in the short term.17 A 2019 meta-analysis18 
of randomised trials of mineralocorticoid receptor 
antagonists in patients with CSCR found that these drugs 
provided a modest improvement in visual acuity. These 
results suggest that inhibiting mineralo corticoid receptors 
could be therapeutically beneficial for patients with CSCR. 
As CSCR predominantly affects men, eplerenone has 
been the preferred treatment option to spironolactone 
because the adverse effect of gynaecomastia is less 
prevalent with eplerenone.19
Despite few clinical trial data, mineralocorticoid receptor 
antagonists are widely used by ophthalmologists as a first-
line therapy for the treatment of CSCR. As these drugs can 
have serious systemic side-effects, such as hyperkalaemia, 
it is important to determine the efficacy and safety profile 
of mineralocorticoid receptor antagonists. Therefore, we 
conducted an adequately powered, randomised, double-
blind, placebo-controlled trial to assess the efficacy and 
safety of eplerenone for treating patients with CSCR.
Research in context
Evidence before this study
Little progress has been made in treating patients with central 
serous chorioretinopathy (CSCR) over the past 150 years. 
Our proposal to do the VICI trial was based on a literature review 
of possible treatments for CSCR that found no conclusive 
evidence supporting the effectiveness of postulated treatments 
in studies published between March, 1969, and January, 2010. 
Our search identified articles in MEDLINE that were indexed with 
medical subject headings (MeSH) for CSCR, chorioretinopathies, 
and central serous retinopathies. We restricted the search using 
the following MeSH subheadings: “pathophysiology of central 
serous chorioretinopathy”, “treatment of central serous 
chorioretinopathy”, and “photodynamic treatment in central 
serous chorioretinopathy”. We searched for additional studies 
from the reference lists of included articles and review articles. 
In addition, we searched the ClinicalTrials.gov database for 
relevant studies using the same search terms. A few small 
phase 1 studies of aflibercept, photodynamic laser therapy, 
and eplerenone were identified, but we found no definitive 
statistically powered studies. The available studies were not 
large enough to detect a clinically important benefit in visual 
acuity (ie, of five or more letters). Consequently, the standard of 
care given to patients with CSCR varies. Photodynamic laser 
therapy and eplerenone are the most frequent treatments 
offered to affected patients.
Added value of this study
The VICI trial is the first randomised, double-blind, placebo-
controlled trial with adequate power to detect a clinically 
important improvement in visual acuity in treating CSCR with 
eplerenone. Visual acuity is a functional outcome of key 
relevance to patients with CSCR. This outcome contrasts with 
the primary outcome of two of three previous trials of 
eplerenone that instead prioritised structural changes in the 
retina. In the VICI trial, neither the primary or the secondary 
outcomes, including time-to-resolution of CSCR or recurrence 
of CSCR after resolution, found any benefit of eplerenone 
treatment over placebo. By virtue of its size, the VICI trial also 
provides the most comprehensive report of adverse events 
compared with other placebo-controlled trials. Instances of 
hyperkalaemia, a known adverse effect of eplerenone, arose in 
as many patients taking placebo as in those taking eplerenone.
Implications of all the available evidence
The VICI trial found no evidence of a clinically important 
benefit of eplerenone for the treatment of CSCR. This result is 
an important outcome that will change clinical practice, 
as eplerenone is commonly used by ophthalmologists as a 
first-line treatment for CSCR. The trial results should prompt 
ophthalmologists to stop using eplerenone to treat patients 
with CSCR and encourage patients to participate in future trials 
of other potential interventions.
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Methods
Study design and participants
The VICI trial was a randomised, placebo-controlled, 
parallel-group, superiority trial done in 22 UK National 
Health Service secondary care hospitals (appendix 
pp 5–6). Patients with chronic CSCR attending outpatient 
ophthalmology clinics were screened in two stages: first 
by consulting patient medical records, and second, if 
patients were initially eligible and after patient consent 
was obtained, trial-specific assessments were done to 
determine eligibility according to additional criteria. Eli-
gibility was decided by experienced ophthalmologists, 
and patient consent was obtained by ophthalmologists or 
experienced research nurses.
Eligibility criteria for the VICI trial have been described 
previously.20 In brief, patients aged 18–60 years with 
treatment-naive CSCR for 4 months or more were eligible 
for inclusion. Patients were excluded if they had choroidal 
neovascularisation or any other disease that could affect 
visual acuity or cause retinal fluid or SRF to accumulate, 
myopia (–6 dioptres or worse), or hyperkalaemia (blood 
serum potassium of >5·0 mmol/L).
All participants provided written informed consent. 
The trial was sponsored by University Hospitals 
Southampton National Health Service Trust and was 
approved by the Wales Research Ethics Committee 
(16/WA/0069) and the Medicines and Healthcare 
products Regulatory Agency (EudraCT 2016-000113-70). 
The protocol has been published.20
Randomisation and masking
Participants were randomly assigned (1:1) to receive either 
eplerenone plus usual care or placebo plus usual care. 
Usual care was included in both groups to ensure 
participants could receive additional treatments, admin-
istered at the clinician’s discretion, if necessary. Ran-
domisation was blocked (random block sizes of two and 
four) and stratified by hospital and visual acuity (low 
[54–67 letters] or high [68–85 letters], read on an Early 
Treatment Diabetic Retinopathy Study [ETDRS] chart). 
The group allocation list was generated by the trial 
statistician using Stata 14.0 (StataCorp, College Station, 
TX, US) before patients were recruited, and the list was 
supplied to Newcastle Specials Pharmacy Production 
Unit (Newcastle upon Tyne, UK). This pharmacy was 
responsible for over-encapsulating eplerenone tablets, 
manufacturing identical placebo capsules, packaging 
capsules in plastic bottles, and labelling the bottles 
identically as clinical trial investigational medicinal 
products (IMPs). Each bottle was labelled with a unique 
number to assign bottles of IMP to participants according 
to their allocated group so that masking could be 
maintained. Production pharmacists had no role in the 
conduct or design of the trial. Participants, clinical teams, 
outcome assessors, hospital pharmacists, and the trial 
management group were all masked to group assignment. 
Unmasking was permitted only if administration of 
emergency treatment was required and only if permission 
from AL or SS was obtained. Unmasking was done by use 
of a secure internet-based IMP management system 
(IMP-Track version 1.0) or, in the event of internet failure, 
by code-break envelopes located in hospital pharmacies.20,21
Before randomisation, information to identify the 
participant and confirm their eligibility was entered 
into a secure internet-based randomisation system 
402 patients assessed for eligibility
114 randomly assigned
57 attended 1-week visit
57 allocated to placebo group and received placebo 
 plus usual care
2 withdrew consent
57 allocated to eplerenone group and received 
 eplerenone plus usual care
288 excluded*
57 attended 1-week visit
54 attended 1-month visit
1 missed visit
56 attended 1-month visit
1 missed visit 
4 withdrew consent
54 attended 3-month visit
   1 missed visit
52 attended 3-month visit
1 missed visit 
54 attended 6-month visit 52 attended 6-month visit
1 withdrew consent1 withdrew consent
52 attended 9-month visit
2 missed visit
51 attended 9-month visit
1 missed visit 
54 attended 12-month visit 51 attended 12-month visit
1 missed visit 
54 analysed for the primary endpoint† 57 analysed for the primary endpoint
57 analysed for the secondary endpoint† 57 analysed for the secondary endpoint
Figure 1: Trial profile
*Reasons for patients being excluded before randomisation are detailed in the appendix (p 69). †Three participants 
in the placebo group withdrew consent without contributing a post-randomisation best-corrected visual acuity 
measurement and were excluded from the primary outcome analysis population and from most secondary 
endpoints analysis populations (see appendix p 92 for the number of patients analysed for each outcome).
Articles
www.thelancet.com   Vol 395   January 25, 2020 297
(GeneSYS version 1.3.1,22 Bristol Trials Centre, Clinical 
Trials and Evaluation Unit, Bristol, UK), which was only 
accessible to approved trial personnel. Ophthalmologists 
or research nurses received a bottle number assigning 
participants to the trial groups within 4 weeks of 
screening and remained successfully masked throughout 
the trial. The randomisation system provided the bottle 
number to be dispensed.
Procedures
Participants in the eplerenone group were prescribed oral 
25 mg/day eplerenone for the first week, increasing to 
50 mg/day for up to 12 months if blood serum potassium 
levels were 5·0 mmol/L or lower. Participants allocated to 
the placebo group followed the same treatment schedule 
to maintain masking. Capsules were taken orally with 
no restrictions on time of day or food consumption. 
Participants were followed up at 1 week, and at 1, 3, 6, 9, 
and 12 months (appendix p 70).20 Sufficient capsules were 
dispensed at each visit to last until the next follow-up 
visit. Participants returned unused capsules at each 
follow-up visit, and the difference between the expected 
and actual number of capsules returned was calculated 
considering the length of time between visits. Participants 
were classified as adherent if more than 70% of the 
capsules that they had been prescribed between follow-up 
visits were taken. Participants stopped taking the study 
drug if SRF had completely resolved at any follow-up 
visit, but treatment was re-started if SRF recurred at a 
subsequent follow-up visit. If the study drug was re-
started, the same dose escalation procedure was followed. 
If serum potassium levels exceeded 5·0 mmol/L at any 
follow-up visit, the study drug was stopped permanently, 
and the participant was invited to continue attending 
follow-up visits up to the end of the 12-month period.
We used a custom-designed database (GeneSYS)22 to 
collect the data . The database allowed: (1) trial personnel 
to enter participant data at each site and to review and 
correct data queries; and (2) the central trial team to 
monitor the accrual of data centrally. We used a separate 
software application (IMP-Track version 1.0) to manage 
the distribution, tracking, and accounting of the IMP 
over the duration of the study.21
Outcomes
The primary outcome was best-corrected visual acuity 
(BCVA) at 12 months, as measured by use of ETDRS 
charts according to a standard protocol for medical retina 
trials.20,23 BCVA was measured at all follow-up visits 
(except at week 1) by accredited optometrists at each site 
who were masked to BCVA results from previous visits 
and the participant’s group allocation. Optometrists were 
certified to perform BCVA assessments in clinical trials 
during site set up.
Secondary outcomes were: low-luminance BCVA; 
central subfield retinal thickness; changes in SRF 
thickness from baseline; systemic and ocular adverse 
events; macular atrophy of the retinal pigment epithelium; 
subfoveal choroidal thickness; choroidal permeability; 
time-to-resolution of SRF; classification of SRF resolution 
Placebo group 
(n=57)
Eplerenone group 
(n=57)
Total
(n=114)
Non-ocular history
Age at randomisation, years 49·9 (7·9) 47·4 (7·1) 48·7 (7·6)
Male 43/57 (75%) 42/57 (74%) 85/114 (75%)
Ethnicity
White 53/57 (93%) 46/57 (81%) 99/114 (87%)
Asian 4/57 (7%) 9/57 (16%) 13/114 (11%)
Mixed 0 1/57 (2%) 1/114 (1%)
Other 0 1/57 (2%) 1/114 (1%)
Systolic blood pressure, mm Hg* 132 (125·0–146·0) 129 (121·0– 141·0) 130 (122·0–144·0)
Diastolic blood pressure, mm Hg* 80 (75·0–88·0) 80 (72·5–88·5) 80 (73·0–88·0)
Heart rate, beats per minute* 68 (60·0–76·0) 73 (66·0–80·0) 72 (63·0–78·0)
Potassium, mmol/L 4 (0·3) 4 (0·4) 4 (0·3)
Smoking status
Current smoker 10/57 (18%) 12/57 (21%) 22/114 (19%)
Previous smoker 16/57 (28%) 25/57 (44%) 41/114 (36%)
Never smoker 31/57 (54%) 20/57 (35%) 51/114 (45%)
Heart failure 0 0 0
Myocardial infarction 1/57 (2%) 0 1/114 (1%)
History of angina 0 0 0
No angina† 57/57 (100%) 57/57 (100%) 114/114 (100%)
New York Heart Association Functional Classification
0 56/57 (98%) 57/57 (100%) 113/114 (99%)
I 1/57 (2%) 0 1/114 (1%)
Transient ischaemic attack 0 0 0
Exposure to steroids 15/57 (26%) 12/57 (21%) 27/114 (23%)
Oral 1/15 (7%) 1/12 (8%) 2/27 (7%)
Inhaled 4/15 (27%) 6/12 (50%) 10/27 (37%)
Intramuscular injection 3/15 (20%) 0 3/27 (11%)
Topical cream 5/15 (33%) 8/12 (67%) 13/27 (48%)
Other 4/15 (27%) 1/12 (8%) 5/27 (18%)
Ocular history
Central subfield retinal thickness 
duration, months
9 (6·0–18·0) 8 (6·0–22·0) 9 (6·0–19·0)
Family history of central serous 
chorioretinopathy
1/57 (2%) 0 1/114 (1%)
Visual acuity score
Low (54–67) 7/57 (12%) 7/57 (12%) 14/114 (12%)
High (68–85) 50/57 (88%) 50/57 (88%) 100/114 (88%)
Best-corrected visual acuity score 78 (73·0–82·0) 77 (73·0–80·0) 78 (73·0–81·0)
Low luminance visual acuity score‡ 64 (57·0–67·0) 57 (50·0–64·0) 60 (52·5–65·0)
Choroidal thickness, µm§ 461 (381·5–534·5) 447 (398·0–509·0) 447 (389·0–521·0)
Subretinal fluid thickness, µm 119 (88·0–178·0) 147 (93·0–196·0) 134 (90·0–194·0)
Central subfield retinal thickness, 
µm
322 (280·0–394·0) 360 (290·0–406·0) 349 (280·0–401·0)
Macular atrophy of retinal pigment 
epithelium
3/55 (5%) 2/56 (4%) 5/111 (5%)
Data are mean (SD), median (IQR), or n/N (%). *Missing data for one patient in the eplerenone group. †According to 
the Canadian Cardiovascular Society grading of angina pectoris. ‡Missing data for one patient in each group. §Missing 
data for one patient in the placebo group.
Table 1: Baseline patient characteristics
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as complete, partial, or none; classification of SRF 
resolution as early, late, or none; time-to-recurrence of 
SRF; fundus fluorescein angiography phenotype; inci-
dence of CSCR in the fellow eye; and patient-reported 
visual function. Outcome measurements and timepoints 
are detailed in the appendix (pp 48–49). All retinal images 
were graded by masked, trained, and quality-assured 
independent graders from the Network of Ophthalmic 
Reading Centres UK.
Adverse events and reactions were recorded throughout 
the 12-month follow-up period. General practitioners 
were notified by recruiting hospitals using a template 
letter approved by the research ethics committee if their 
patient was a trial participant, and practitioners were 
asked to inform the local research team about any 
suspected adverse events or reactions to the drug. At 
each follow-up visit participants were asked to report 
any adverse events since the previous visit. All adverse 
events were recorded on a form that categorised them by 
the Medical Dictionary for Regulatory Activities system 
organ class (version 14.1; appendix p 35).20
Statistical analysis
A target sample size of 104 patients was chosen for the 
trial to have 90% power to detect a difference of five or 
more letters between the two groups (two-tailed test at 
an α level of 0·05) assuming that less than 15% of 
participants would drop out during the follow-up period. 
The following assumptions were made: one study eye 
per participant; a SD of nine letters; a correlation 
coefficient of 0·5 between BCVA measured at baseline 
and at any follow-up assessment; a minimum of two 
follow-up assessments per participant, with a correlation 
coefficient of 0·8 between BCVA measured at follow-up 
assessments.
Analyses were directed by a prespecified statistical 
analysis plan (appendix pp 46–67) and done on a 
modified intention-to-treat basis (ie, participants who 
withdrew consent without contributing a post-random-
isation BCVA measurement were excluded from the 
primary analysis popu lation and from most secondary 
analysis populations [see appendix p 92 for number of 
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Figure 2: Best-corrected visual acuity over 12-month follow-up period
Mean difference at 12 months was 1·73 (95% CI –1·12 to 4·57), p=0·236.
Placebo group (n=57) Eplerenone group (n=57) MD or HR (95% CI) p value
Primary outcome
Best-corrected visual acuity at 12 months 79·5 (4·5) 80·4 (4·6) MD 1·73 (–1·12 to 4·57) 0·236
Secondary outcomes
Low luminance visual acuity at 12 months 65·3 (3·7) 63·9 (4·8) MD 0·61 (–3·79 to 5·02) 0·785
Central subfield retinal thickness at 12 months, µm 270·0 (38·0) 302·1 (43·7) MD 24·35 (–7·86 to 56·56) 0·142
Subretinal fluid thickness at 12 months, µm* 72·5 (6·2) 120·7 (6·0) MD 48·08 (13·43 to 82·73) 0·0066
Macular atrophy of the retinal pigment epithelium at 12 months 3/53 (6%) 4/49 (8%) ·· ··
Change in area of macular retinal pigment epithelium hypoautofluorescence 
at 12 months, mm²†
0·03 (0·03 to 0·04) 0·72 (–0·73 to 2·10) ·· ··
Choroidal thickness at 12 months, µm* 451·4 (78·6) 478·0 (58·1) MD 38·53 (12·31 to 64·74) 0·0040
Reduced choroidal permeability at 12 months 3/54 (6%) 1/49 (2%) ·· ··
Visual function questionnaire-25 overall composite score at 12 months* 89·1 (4·4) 86·5 (5·3) MD 2·39 (–5·45 to 0·68) 0·127
Estimated median time to complete resolution of subretinal fluid, days‡ 458·2 (214·1 to 702·2) 603·3 (313·1 to 893·5) HR 0·78 (0·41 to 1·51) 0·463
Estimated median time to complete or partial resolution of subretinal fluid, 
days‡
184·2 (122·3 to 246·0) 141·1 (57·9 to 224·4) HR 1·23 (0·75 to 2·01) 0·418
Estimated median time to recurrence of subretinal fluid, days‡§ 192·1 (136·6 to 247·6) 182·5 (117·7 to 247·3) HR 1·10 (0·45 to 2·66) 0·836
New central serous chorioretinopathy in the fellow eye 4/57 (7%) 5/57 (9%) ·· ··
Data are presented as median (IQR), mean (SD), or n/N (%). Formal statistical comparisons of treatment effects were not done if ten or fewer patients in total did not experience or achieve the outcome. 
MD=mean difference. HR=hazard ratio. Total numbers of patients analysed for each outcome are listed in the appendix (p 92). *Multiple imputation (ten imputed datasets) was used to account for missing data. 
†Not formally tested, as only eight patients from both groups had macular retinal pigment epithelium hypoautofluorescence at baseline, at 12 months, or at both time points. ‡Median time to resolution or 
recurrence predicted from an interval-censored survival model. §Assumed that resolution occurred in the middle of the interval between the visit when the resolution status was negative and the first visit when 
the resolution status was positive.
Table 2: Descriptive statistics for primary and secondary outcomes
For more on the Network of 
Ophthalmic Reading Centres UK 
see http://www.networcuk.com/
Articles
www.thelancet.com   Vol 395   January 25, 2020 299
patients analysed for each outcome]). Continuous data 
are summarised by the mean (SD) or median (IQR) 
if distributions were skewed, and categorical data are 
reported as a number and percentage. Linear regression 
was used to compare continuous outcomes, proportional 
hazards parametric survival models were used for 
interval-censored data (time-to-event outcomes), and 
mixed effects regression was used for continuous 
longitudinal outcomes. Standard methods and trans-
formations were used to assess model fit; however, 
alternative methods of assessment were sought if 
model fit was inadequate. Analyses were adjusted for 
the stratification factors of baseline visual acuity 
(54–67 letters vs 68–85 letters) fitted as a fixed effect and 
centre-fitted as a random effect. Centres with a small 
number of participants were combined to to ensure 
that the treatment-effect of interest could be estimated 
reliably (appendix p 77). For time-to-event outcomes, a 
clustered sandwich estimator was used to adjust the SEs 
for clustering within centres, as it was not possible to fit 
Placebo (n=57) Eplerenone (n=57)
All events Serious adverse events All events Serious adverse events
Number of 
patients (%)
Number of 
events
Number of 
patients (%)
Number of 
events
Number of 
patients (%)
Number of 
events
Number of 
patients (%)
Number of 
events
Any event (anticipated or unanticipated) 31 (54%) 72 3 (5%) 3 30 (53%) 95 0 0
Anticipated ocular events in study or non-study eyes*†
Study eye events 0 0 0 0 0 0 0 0
Decrease in visual acuity of 
≥15 letters
0 0 0 0 0 0 0 0
Incident choroidal 
neovascularisation
0 0 0 0 0 0 0 0
Non-study eye events 0 0 0 0 1 (2%) 2 0 0
Decrease in visual acuity of 
≥15 letters
0 0 0 0 1 (2%) 1 0 0
Incident choroidal neovascularisation 0 0 0 0 1 (2%) 1 0 0
Anticipated systemic events‡ 
Infections and infestations 3 (5%) 4 0 0 8 (14%) 10 0 0
Infection 3 (5%) 4 0 0 8 (14%) 10 0 0
Pharyngitis 0 0 0 0 0 0 0 0
Pyelonephritis 0 0 0 0 0 0 0 0
Eosinophilia 0 0 0 0 0 0 0 0
Hypothyroidism 0 0 0 0 0 0 0 0
Metabolism and nutrition disorders 9 (16%) 9 0 0 8 (14%) 8 0 0
Dehydration 0 0 0 0 0 0 0 0
Hypercholesterolaemia 1 (2%) 1 0 0 0 0 0 0
Hyperkalaemia 8 (14%) 8 0 0 8 (14%) 8 0 0
Hypertriglyceridaemia 0 0 0 0 0 0 0 0
Hyponatraemia 0 0 0 0 0 0 0 0
Insomnia 0 0 0 0 0 0 0 0
Nervous system disorders 8 (14%) 10 0 0 7 (12%) 9 0 0
Dizziness 3 (5%) 3 0 0 4 (7%) 4 0 0
Headache 6 (11%) 7 0 0 3 (5%) 5 0 0
Hypoaesthesia 0 0 0 0 0 0 0 0
Syncope 0 0 0 0 0 0 0 0
Cardiac disorders 2 (4%) 2 1 (2%) 1 3 (5%) 5 0 0
Atrial fibrillation 0 0 0 0 0 0 0 0
Left ventricular failure 0 0 0 0 0 0 0 0
Myocardial infarction 1 (2%) 1 1 (2%) 1 0 0 0 0
Tachycardia 1 (2%) 1 0 0 3 (5%) 5 0 0
Vascular disorders 0 0 0 0 0 0 0 0
Arterial thrombosis limb 0 0 0 0 0 0 0 0
Hypotension 0 0 0 0 0 0 0 0
Orthostatic hypotension 0 0 0 0 0 0 0 0
(Table 3 continues on next page)
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the centre as a random effect. For continuous outcomes 
measured at baseline and at one or more subsequent 
follow-up visits, baseline values were modelled as a 
covariate. Models for longitudinal outcomes included 
both time and time-by-treatment interaction terms fitted 
as fixed effects so that the treatment effect at 12 months 
could be estimated. Different variance or covariance 
structures were explored and the structure that provided 
the best fit in terms of likelihood ratio tests was used to 
model within patient errors. An unstructured covariance 
structure provided the best fit in all models. Multiple 
imputation (ten imputed datasets) was used to account 
for missing data. Placebo plus usual care was the 
reference group in all analyses. Likelihood ratio tests 
were used to determine statistical significance when 
possible, and results are reported as effect estimates 
with 95% CIs. A prespecified exploratory analysis was 
done to assess the effect of adherence and treatment on 
the primary outcome. Sensitivity analyses included 
adjusting time-to-event outcomes for baseline imbal-
ances in prognostic factors and reassessing the effect of 
adherence and treatment on the primary outcome after 
Placebo (n=57) Eplerenone (n=57)
All events Serious adverse events All events Serious adverse events
Number of 
patients (%)
Number of 
events
Number of 
patients (%)
Number of 
events
Number of 
patients (%)
Number of 
events
Number of 
patients (%)
Number of 
events
(Continued from previous page)
Cough 2 (4%) 2 0 0 3 (5%) 3 0 0
Gastrointestinal disorders 6 (11%) 10 0 0 9 (16%) 19 0 0
Constipation 0 0 0 0 1 (2%) 1 0 0
Diarrhoea 2 (4%) 3 0 0 2 (4%) 2 0 0
Flatulence 0 0 0 0 1 (2%) 1 0 0
Nausea 5 (9%) 7 0 0 4 (7%) 7 0 0
Vomiting 0 0 0 0 4 (7%) 8 0 0
Skin and subcutaneous tissue disorders 1 (2%) 1 0 0 5 (9%) 5 0 0
Angioedema 0 0 0 0 0 0 0 0
Hyperhidrosis 0 0 0 0 1 (2%) 1 0 0
Pruritus 0 0 0 0 2 (4%) 2 0 0
Rash 1 (2%) 1 0 0 2 (4%) 2 0 0
Musculoskeletal and connective tissue 
disorders
5 (9%) 8 0 0 11 (19%) 11 0 0
Back pain 2 (4%) 3 0 0 3 (5%) 3 0 0
Muscle spasms 0 0 0 0 1 (2%) 1 0 0
Musculoskeletal pain 5 (9%) 5 0 0 7 (12%) 7 0 0
Renal impairment 0 0 0 0 0 0 0 0
Cholecystitis 0 0 0 0 0 0 0 0
Gynaecomastia 0 0 0 0 0 0 0 0
General disorders and administration 
site conditions
0 0 0 0 2 (4%) 2 0 0
Asthenia 0 0 0 0 1 (2%) 1 0 0
Malaise 0 0 0 0 1 (2%) 1 0 0
Investigations 0 0 0 0 1 (2%) 1 0 0
Increased blood creatinine 0 0 0 0 1 (2%) 1 0 0
Increased blood glucose 0 0 0 0 0 0 0 0
Increased blood urea 0 0 0 0 0 0 0 0
Decreased epidermal growth factor 
receptor
0 0 0 0 0 0 0 0
Any anticipated event§ 25 (44%) 46 1 (2%) 1 28 (49%) 75 0 0
Any unanticipated event§ 16 (28%) 26 2 (4%) 2 13 (23%) 20 0 0
*Anticipated ocular events were specified in the protocol and were not coded using the Medical Dictionary for Regulatory Activities system organ class; they were recorded 
for both designated study eyes and non-study eyes. †At baseline, participants were assigned a study eye, which was defined as either the only eye with chronic serous 
chorioretinopathy or, if both eyes had the disease, the eye with worse disease; the other eye was classified as the non-study eye. ‡Anticipated systemic events were coded 
according to the Medical Dictionary for Regulatory Activities system organ class. §Some patients had both anticipated and unanticipated events and appear in both rows; 
therefore, the sum of the numbers of patients with any anticipated and any unanticipated event will be greater than the number of patients with any event (anticipated or 
unanticipated). 
Table 3: Ocular and systemic adverse events
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imputing pill counts for lost bottles. Two post-hoc 
analyses were used to: (1) re-estimate the treatment 
effects for BCVA, central subfield retinal thickness, 
SRF thickness, and choroidal thickness after adjusting 
for PDT admin istered during follow-up, and; (2) analyse 
choroidal thickness in the other eye.
To put our findings into context, we did a systematic 
review and meta-analysis of other trials that compared 
eplerenone with placebo. Our search identified articles 
in MEDLINE that were indexed with the following 
Medical Subject Heading terms: “central serous choroidal 
retinopathy” AND (“eplerenone” OR “mineral o corticoid 
receptor antagonists”) AND (“publication type=randomized 
controlled trial”). We assessed the risk of bias,24 and re-
analysed data reported in the trials to identify treatment 
effects for BCVA and SRF thickness using the same metric 
(ie, the difference in the change in BCVA and SRF 
thickness from baseline to the end of treatment between 
the two groups). If it was not possible to calculate the SD 
of the mean change from baseline for a group, an average 
of the SDs from the other studies was used. The treatment 
effects were synthesised in a fixed-effects meta-analysis 
to estimate weighted mean differences (MDs) between 
eplerenone and placebo groups according to the inverse 
variance method.
Data were analysed with Stata version 15.1 (StataCorp, 
LP, College Station, TX, USA). Further details of the 
statistical analyses are provided in the statistical analysis 
plan (appendix pp 46–67).
The trial was overseen by an independent data 
monitoring and safety committee who reported their 
recommendations to an independent trial steering 
committee (appendix p 68). The trial is registered with 
ISRCTN, ISRCTN92746680.
Role of the funding source
The funder and the sponsor of the study had no role in 
study design, data collection, data analysis, data inter pre-
tation or writing of the report. The corresponding author 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
A total of 402 patients were screened for inclusion 
and 305 were identified as initially eligible. Of the initially 
eligible patients, 223 were approached, and 179 consented 
to participate. 64 patients were subsequently identified 
as ineligible and one patient withdrew their consent 
(appendix p 69). Between Jan 11, 2017, and Feb 22, 2018, 
we randomly assigned 114 patients to receive either 
eplerenone plus usual care (57 patients) or placebo plus 
usual care (57 patients; figure 1).
111 patients attended at least one post-randomisation 
visit in which BCVA was measured. Three participants in 
the placebo group withdrew consent without contributing 
a post-randomisation BCVA measurement and were 
excluded from the primary analysis population and most 
secondary analysis populations (appendix p 92); two 
participants withdrew consent after the 1-week visit, and 
one participant did not attend the 1-month and 3-month 
follow-up visits and withdrew consent after 3 months 
without attending any further visits. Nine scheduled 
follow-up visits were missed by participants who had not 
withdrawn their consent at the time (four visits were 
missed by three patients in the placebo group and five 
visits were missed by three patients in the eplerenone 
group). Adherence to taking the capsules was similar 
between the two groups (appendix p 76). There were no 
instances of a participant receiving the wrong drug 
and only a few instances of other protocol deviations, 
apart from the number of visits attended outside the 
prespecified visit window (62 visits by 31 patients in 
the eplerenone group and 53 visits by 30 patients in the 
placebo group; appendix pp 72–73). During follow-up, 
six patients in the placebo group and three patients in 
the eplerenone group received PDT as usual care and 
one participant in the placebo group received sub-
threshold laser therapy as usual care (appendix p 76).
Baseline patient characteristics by group are shown in 
table 1. There was no difference in the median duration 
of treatment (time during follow-up when participants 
were taking their allocated capsules) between groups 
(9·1 months in the eplerenone group and 8·8 months in 
the placebo group; appendix pp 74–75).
Modelled mean BCVA at 12 months was 80·4 letters 
(SD 4·6) in the eplerenone group and 79·5 letters 
(SD 4·5) in the placebo group. On average, BCVA 
increased by approximately four letters in both groups 
during follow-up (figure 2). No difference in BCVA at 
12 months between the two groups was observed 
(estimated MD 1·73 letters [95% CI –1·12 to 4·57]; 
p=0·24; table 2). The exploratory analysis found that 
adherence and duration of treatment had no effect on 
BCVA, irrespective of whether pill counts were imputed 
for lost IMP bottles (appendix p 93). The post-hoc 
analysis, which adjusted for the estimated diff erence in 
BCVA between groups for PDT administered during 
follow-up, did not change this result (appendix p 93).
Results for secondary outcomes and treatment effects 
by group are described in table 2 and the appendix 
(pp 78–85). There were no significant differ ences between 
groups in favour of eplerenone treatment. In addition, 
there were no apparent differences in the pattern of 
complete resolution of SRF or recurrence of CSCR (with 
or without adjustment for baseline SRF thickness) 
between the two groups (appendix p 93). Furthermore, 
central subfield retinal thickness at 12 months did not 
differ significantly between the two groups (MD 24·35 µm 
[95% CI −7·86 to 56·56]; p=0·14), but a significant dif-
ference in SRF thickness favouring placebo at 12 months 
was observed (MD 48·08 µm [95% CI −13·34 to 82·73]; 
p=0·0066).
Serum potassium levels were similar in both groups 
during follow-up (appendix p 75). Levels greater than 
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5·0 mmol/L prompted discontinuation of the IMP in 
eight (14%) participants in each group. Results for all 
serious adverse events and other adverse events are 
shown in table 3. Three serious adverse events were 
reported in the placebo group, and none of these events 
were considered to be associated with the IMP.
The results of the systematic review and meta-analysis 
can be found in the appendix (pp 94–98). Three trials25–27 
compared eplerenone with placebo in 40 eyes over 
1 month of treatment, 21 eyes over 2 months of treatment, 
and 19 eyes over 3 months of treatment. The fourth trial 
included in the meta-analysis was the VICI trial, which 
analysed 111 eyes over 12 months of treatment. The pooled 
difference in the mean change in BCVA between the 
placebo and eplerenone groups was 0·06 logarithm of the 
minimum angle of resolution (95% CI −0·09 to −0·02; 
equivalent to 3·0 letters and −4·5 to −1·0 ETDRS letters; 
I² 31%). The pooled difference in SRF thickness was 
−26·7 µm (95% CI −63·1 to 9·8; I² 84%).
Discussion
The result for the primary outcome of the VICI trial 
excludes the target difference that the VICI trial was 
powered to detect (an upper 95% confidence limit of 
4·57 letters), indicating that treatment with eplerenone 
did not improve BCVA by five or more letters compared 
with placebo at 12 months of follow-up. There was 
no difference in the median times to complete resolution 
of SRF or subsequent recurrence of CSCR, and no 
difference in several measurements of retinal mor-
phology, between the two groups. Of particular note, 
two retinal morphology outcomes (SRF thickness and 
choroidal thickness) significantly favoured placebo. The 
reasons for these results are unclear. The findings for 
BCVA, time-to-event outcomes, and key morphological 
outcomes were unaltered in sensitivity, exploratory, or 
post-hoc analyses. The absence of any difference in 
outcomes between the eplerenone and placebo groups 
favouring eplerenone cannot be explained by weak-
nesses in trial conduct. The primary analysis included 
97% of randomised patients, and overall, these patients 
attended 99% of all scheduled visits. In addition, there 
were no protocol deviations that could have affected the 
treatment comparison.
The results of the meta-analysis are consistent with the 
VICI trial results, as the point estimates for the mean 
change in BCVA and SRF thickness from baseline to the 
end of treatment in the VICI trial lie within the 95% CIs 
for the pooled estimates from the meta-analysis. The 
pooled difference in mean change in BCVA also excludes 
the target differ ence that the VICI trial was powered to 
detect (upper 95% confidence limit, –4·5 letters). However, 
the pooled differences in SRF show substantial hetero-
geneity, and the effect of treatment with eplerenone on 
SRF thickness in the VICI trial opposed the treatment 
effects of this drug in the other three trials included in the 
meta-analysis. The reason for these inconsistent results is 
unclear. However, it is possible that the effect of eplerenone 
on SRF thickness is short-lived, and shorter follow-up 
intervals (eg, every 4 weeks) might have provided more 
data and allowed a more detailed comparison of response 
to treatment with eplerenone and placebo.
Notwithstanding the risk of bias assessment, we have 
concerns about the quality of the three small trials25–27 
included in the meta-analysis (appendix p 95). One trial25 
was not registered despite being published in 2016. We 
were unable to find a published protocol or prespecified 
analysis plan for any of the trials, and the reported 
analyses of treatment effects were unusual, suggesting 
selection of the reported result.24 In our meta-analysis, we 
avoided bias from selection of the reported result by re-
analysing the published data.
The VICI trial had several strengths. All but three 
participants contributed to the primary analysis and 
participants attended almost all scheduled visits. There 
were no protocol deviations that compromised the 
treatment comparisons. The trial was powered to detect a 
clinically important difference in BCVA; a measure that 
is being used by several large multicentre trials of 
treatments for retinal conditions. In fact, the VICI trial 
had more power than anticipated because participants 
attended almost all scheduled visits.28,29
Limitations of the trial included the need to discontinue 
treatment if CSCR resolved completely during follow-up 
or if an elevation in serum potassium levels was detected. 
Hyperkalaemia was not a common side-effect in patients 
included in this trial, as they were younger and fitter 
(ie, all but one patient was classified as class 0 according 
to the New York Heart Association Functional Classi-
fication system, and no patients had angina) than patients 
who are usually prescribed eplerenone for heart failure. 
These limitations might have reduced the observed 
treatment effect, but they were required to ensure the 
safety of participants. As such, we compared recurrence 
of CSCR after complete resolution and found no 
difference between the two groups. Our inability to 
control the use of co-treatments could have introduced 
bias if they were used differen tially in each group (ie, if 
they had been administered to more patients in one 
group than another). Of note, more patients in the 
placebo group were given PDT than in the eplerenone 
group. However, co-treatments (including PDT) were 
used rarely in patients overall, and the post-hoc analysis 
showed that the results were not affected after adjusting 
for the small difference in the number of patients who 
were given PDT in each group.
In summary, the VICI trial found no evidence of a 
clinically important benefit of eplerenone for the treat ment 
of CSCR. This result is an important outcome that will 
change clinical practice. The trial results should prompt 
ophthalmologists to stop prescribing eplerenone to treat 
CSCR and encourage patients to participate in future 
trials of other potential interventions. CSCR remains a 
devastating condition for people (aged 18–60 years) who 
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are affected, and it remains a challenging condition for 
ophthalmologists to manage.
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